Christina Coughlin

Biography

Chris joined Immunocore as Chief Medical Officer in April 2015. She has extensive experience in oncology drug development, with expertise in both clinical development and translational medicine. Prior to joining Immunocore Chris led two early development programmes at Novartis in checkpoint inhibition and PI3 kinase inhibition. She has also served as International Project Team Leader at Morphotek Inc., the monoclonal antibody company acquired by Eisai Co. Ltd in 2007, where she led the early clinical development team responsible for monoclonal antibody development against novel targets. Chris graduated with an M.D. and Ph.D from the University of Pennsylvania, where she studied patient responses to tumour antigens with Dr Robert Vonderheide in the division of Translational Research under the direction of Dr Carl June.  

Research Interest

  Christina has research interest in oncology, drug  development.